Summary Progression through G, phase of the eukaryotic cell cycle is tightly controlled by cyclin-dependent kinases (CDK). These proteins form part of a regulatory pathway including the cyclin-dependent kinase inhibitor (CKI) p16, D-type cyclins and the product of the retinoblastoma gene pRb. Aberration of any one of these components may lead to uncontrolled proliferation contributing to neoplasia. Three of these proteins, cyclin Dl, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relative to normal. Genetic analysis of the gene encoding cyclin Dl (CCND1) was also carried out, using an intragenic restriction fragment-length polymorphism (RFLP) to assess possible allelic imbalance. A majority of the tumours studied (-90%) showed abnormalities in expression of at least one of these proteins. Overexpression of cyclin Dl was found in -49% cases, reduced expression of p16 in -46% and reduced expression of pRb in -37%. Allelic imbalance of cyclin Dl was found in -57% cases.
al, 1995) and loss of p16 (Reed et al, 1995; Sonoda et al, 1995) and pRb (Harbour et al, 1988; Geradts et al, 1994) .
These cell cycle components have been studied by various means in invasive breast tumours. Cyclin DI is found within chromosome band 1lq13, which is amplified in -15-20% of primary breast cancers (Fantl et al, 1990; Lammie et al, 1991) , and overexpression of cyclin Dl at the mRNA level has been reported for an even greater proportion of breast cancers (Buckley et al, 1993) . More recently, it has been possible to look directly at cyclin Dl protein expression by means of immunohistochemistry using a monoclonal antibody to the protein. Approximately half of primary breast carcinomas studied showed overexpression/accumulation of the cyclin Dl protein (Bartkova et al, 1994; Gillett et al, 1996) .
The relationship between the Rb gene and breast cancer is complex, with loss of heterozygosity of the Rb locus not necessarily being related to mutation or physical deletion of the Rb gene or to reduced expression of the protein (Borg et al, 1992; Wadayama et al, 1994; Berns et al, 1995) . Consequently, studies on pRb expression may yield more information on the role of Rb in breast cancer. Loss of pRb expression has been found to correlate with more advanced and less differentiated mammary tumours (Varley et al, 1989) .
The role played by p16 in breast carcinogenesis is also unclear. Despite the initial discovery of homozygous deletions of p16 in human tumour cell lines, including those derived from invasive breast tumours, mutational analysis of primary breast tumours indicated that mutations ofp16 in breast tumours are rare Brenner and Aldaz, 1995) . Therefore, direct analysis of the p16 protein by immunohistochemistry was again expected to yield more relevant information than could be obtained from genetic analysis.
Work on preinvasive breast lesions has been more limited. In this study, three panels of tumours were available: purely in situ tumours (DCIS), invasive tumours with a DCIS component and, for comparison, purely invasive tumours. Immunohistochemical Analysis of allelic imbalance of the cyclin Dl gene
The recent identification of a polymorphism within the cyclin DI coding sequence (Betticher et al, 1995) 
British Journal of Cancer (1998) containing the restriction site: Cy 26 5' GTG AAG TTC ATT TCC AAT CCG C-3'; Cy 27 5'-GGG ACA TCA CCC TCA CTT AC-3'. The arrangement of these primers is shown in Figure 1 .
Reactions were carried out in a final volume of 50 gl containing lx PCR buffer, 250 gM dNTPs, 6 ng p1l-each of forward and reverse primer and 0.5-2 units Thermoprime plus DNA polymerase (Advanced Biotechnologies). Normal and tumour DNA from each case was used as template, either 2-5 pl of DNA extracted from microdissected tissue or 1 gl of blood/tumour DNA from the invasive breast cancer cases. Reaction conditions included an initial denaturation step of 94°C for 4 min followed by 37 cycles each of 94°C for 1 min, 60°C for 1 min and 74°C for 1 min with a final extension step of 72°C for 10 min. Twenty microlitres of PCR product were digested with 1 unit of ScrFI restriction enzyme in lx enzyme buffer in a total volume of 50 ,l. After incubation at 37°C for 3 h, digestion products were visualized on a 2% agarose gel. Cases heterozygous for this RFLP showed two fragments after digestion. These could be assessed for allelic imbalance of cyclin DI, by comparison of the intensity of the alleles in the tumour compared with normal.
Immunohistochemistry
Formalin-fixed paraffin sections (4,M) were prepared on 3-aminopropyltriethoxysilane-coated slides. After dewaxing in xylene, the sections were immersed in 300 ml of methanol containing 10 ml of hydrogen peroxide for 15 min to block endogenous peroxidase and then were rinsed thoroughly in water. When using the antibodies to cyclin Dl and pRb the sections were placed in citrate buffer (pH 6.0) and boiled for 5 min in a microwave. The solution was allowed to stand for 5 min before bringing to the boil again, for a further 5 min. Once the buffer had cooled to room temperature, the slides were washed well with water and rinsed in Tris-buffered saline (TBS, pH 7.6). Sections were covered with 1:100 goat serum for 20 min at room temperature. This was removed by tapping the slides on absorbent paper, rather than by further washing. Sections were then incubated overnight at room temperature in a humidified container, with either primary antibody or goat serum as a negative control to confirm the specificity of the immunostaining reaction.
The mouse monoclonal cyclin Dl antibody DCS-6 (Novocastra) was used at a 1:100 dilution in 1% bovine serum albumin (BSA) and the mouse monoclonal pRb antibody (NCL-RB1, Novocastra) was used at a 1:50 dilution in 1% BSA. The mouse monoclonal antihuman p16 antibody (Pierce) was diluted 1:150 in TBS and was used in a similar protocol to that described above, but omitting the antigen retrieval step. Primary antibody was removed by two washes with TBS, each for 3 min. This was then replaced with 1:100 biotinylated goat anti-mouse/rabbit Ig (Dako) for 30 min at room temperature. After a further two washes with TBS, the sections were incubated in 1:100 solution of streptavidin-biotin complex/horseradish peroxidase (Dako) for 30 min at room temperature, rewashed in TBS twice and covered in 3,3'-diaminobenzidine tetrahydrochloride (1 mg ml-' DAB, Dako) for 10 min. After a thorough rinse in water, sections were counterstained with 2x Gills haematoxylin, washed in water, cleared, dehydrated and mounted.
Assessment of staining patterns
Staining was assessed according to the intensity of the majority of cells and particular attention was paid to the localization of the staining; cytoplasmic or nuclear. For the cyclin Dl staining, comparisons were made with the staining pattern of a positive control for cyclin D1; a breast carcinoma known to overexpress cyclin D1. For the p16 staining, a negative control for p16, the breast carcinoma cell line MDA-MB-23 1, which has a deletion of p16, was included. A description of the observed staining pattern was noted and cases graded accordingly. All cases were rescored to confirm the initial result and a selection of cases was independently assessed by an experienced histopathologist (Dr F Knox) for further confirmation.
The criteria for a 'normal' staining pattern was dependent on the protein being studied. For cyclin D1 when normal ducts were present on the section, the staining pattern in these cells was considered to be normal and used as a comparison to Table 1 . These cases were assessed for allelic imbalance in the tumour, which would appear as an increased/decreased intensity in one allele relative to the other allele in the tumour and relative to the same allele in the normal DNA. Such imbalance was found in eight cases (57%), some of which have allelic imbalance in more than one component of the same tumour, such as case 6457. This was assumed to be representative of amplification of the cyclin Dl gene, as there is much evidence to suggest that cyclin DI behaves as an oncogene and a number of previous studies have shown the gene to be activated by amplification (Fantl et al, 1990; Lammie et al, 1991) .
Information gained from this technique was then complemented by immunohistochemical analysis of the cyclin DI protein and other cell cycle proteins.
Results of immunohistochemistry
Results from each of the three tumour sets stained with all three antibodies are represented in Table 2 2A-C. Staining patterns varied from predominantly nuclear with a small background level of cytoplasmic staining to predominantly cytoplasmic with only a small percentage of positive nuclei, to equally strong staining in both the nucleus and the cytoplasm, to exclusively cytoplasmic staining or to no staining at all. The positive control breast carcinoma known to overexpress cyclin DI invariably showed positive nuclear staining of a proportion of cells. The no-antibody negative controls included for each section did not show any staining.
The results of the genetic and immunohistochemical analysis of cyclin Dl carried out in this study are reasonably consistent with previous work looking at amplification of the gene and overexpression of the protein in human breast cancer. The finding that increased protein expression is not always accompanied by gene amplification and that some cases with amplification do not show increased expression (Table 1 ) is in agreement with the results of a study by Buckley et al (1993) . This study provides additional information on purely DCIS lesions and invasive lesions with an intraductal component. In contrast to many previous studies on a range of malignancies (Bartkova et al, 1994 (Bartkova et al, , 1995 Michalides et al, 1996) , which have reported predominantly nuclear staining and tended to regard cytoplasmic staining as an insignificant artefact, the cyclin DI protein in this study was frequently observed at high levels within the cytoplasm. Taking into account the strength of staining, combined with the marked contrast in staining results obtained from material prepared in the same way, it is reasonable to assume that strong cytoplasmic staining in one case compared with weak cytoplasmic staining in another case does reflect a true difference in expression of the cyclin DI protein between the two tumours and is unlikely to be as a result of the fixation. A similar pattern of exclusively cytoplasmic staining, or cytoplasmic staining in combination with nuclear staining, has previously been observed in non-small-cell lung cancers (Betticher et al, 1996) . In addition, an earlier in vitro study looking at expression of cyclin Dl and D2 (Lukas et al, 1995b) in U-2-OS sarcoma cells found both proteins to have a subcellular nuclear localization during mid to late Gp, in contrast to a cytoplasmic and nuclear localization at the G,-S transition. The possible reason given for this was a change of solubility of the proteins, due to a loss of a selective nuclear anchor at the G,-S transition.
Expression of pRb A range of staining patterns was observed for pRb and is shown in Figure 2D and E. Commonly, strong nuclear staining was apparent in a majority of cells, accompanied by some cytoplasmic staining. However, in some cases nuclear staining was visible in only a small proportion of cells, whereas strong cytoplasmic staining was visible in all cells. Exclusively cytoplasmic staining was scored as loss of pRb. Abnormally low levels of pRb in the nucleus were considered to be '+' or '-', a pattern that is seen in 19 (-46%) cases in total ( Table 2) . As this is likely to lead to a loss in the 'brakes' on the cells' proliferation, reduced expression of pRb may have played some part in the progression to neoplasia.
Expression of p16
Despite the fact that like pRb, p16 is a tumour suppressor and is thought to carry out its functions within the nucleus, many sections had evidence of cytoplasmic staining, sometimes alone ( Figure   2F ) and sometimes in combination with nuclear staining. When this cytoplasmic staining was weak '+', it was considered to be residual non-specific staining. However, for several cases, the intensity of the cytoplasmic staining was such that it could not be ignored. As antibodies for p16 are relatively new, information on staining patterns found in various tissues and tumours is limited. In addition, much remains to be learned about the expression patterns and functions of pI6. Fifteen cases (-37%) showed reduced expression of p16 relative to normal.
Relationship between expression of cyclin DI, pRb and p16
There is evidence to suggest that both pRb and cyclin DI are involved in an autoregulatory feedback loop mechanism that controls progression through GI phase. It has been observed that Rb-deficient tumour cell lines have very low levels of cyclin DI and cyclin D/CDK complexes (Bates et al, 1994) . As can be seen from the results in Table 2 , this type of correlation has been observed in a number of cases from this study, with notable exceptions. Twelve of the 15 cases showing reduced expression of pRb (80%) have a correspondingly low level of cyclin Dl expression ('+' or '-'), including case 1960 and case 613, providing support for an autoregulatory relationship between cyclin Dl and pRb. In contrast to this, the remaining three cases showing low pRb levels have varying degrees of cyclin Dl overexpression, for example case 4410, which has strong nuclear positivity for cyclin DI in a majority of cells.
A number of studies have also reported an inverse relationship between expression of p16 and pRb (Otterson et al, 1994; Shapiro et al, 1995; Yeager et al, 1995; Sakaguchi et al, 1996; Ueki et al, 1996) , suggesting the existence of a negative feedback loop between these two cell cycle proteins. In a model for G1-S phase progression, phosphorylation of pRb by activated CDKs results in the release of sequestered transcription factors and subsequent transcription of genes required for S-phase. One of these genes may be pi6 itself, as it has been found that p16 accumulates to a high level in cells lacking functional pRb (Li et al, 1994) . The p16 protein produced in this way would then be available to inhibit the kinase activity of the CDKs and so transcription factors would again be sequestered by pRb. If this model is correct, any deficiency of pRb, whether due to alterations of the gene or other changes affecting the protein levels, would be likely to result in deregulated transcription of genes involved in G,-S progression and include accumulation of p16 protein.
Of the nineteen cases with reduced expression of pRb, only -10% show corresponding accumulation (+++) of p16 protein. For example, case 3144 shows normal expression of pRb in normal ducts and lack of expression in invasive cells, with a corresponding increase in expression of p16 in the invasive cells relative to normal, which would agree with the proposed model discussed above. The remaining 90% show a lower level or complete loss of p16 expression and therefore, in common with other studies (Wang and Becker, 1996) , do not show an inverse relationship between pRb and p16. (1998) 77(9) (Gillett et al, 1996) . Reduced (Sicinski et al, 1995) . The mammary glands of mice lacking cyclin DI fail to undergo the intense proliferation induced by the ovarian steroids that normally accompanies pregnancy, confirming that cyclin Dl plays a critical role in the regulation of mammary epithelial proliferation.
Other studies have been suggestive of a role for cyclin DI overexpression in transformation of breast epithelial cells. In a recent publication looking at a range of preinvasive and invasive breast lesions (Weinstat-Saslow et al, 1995) , cyclin DI mRNA was found to be overexpressed in DCIS and invasive cases, but not in cases of atypical ductal hyperplasia (ADH). However, there appears not to be a straightforward relationship between cyclin DI and prognosis. Early studies related cyclin DI amplification to poor prognosis (Schuuring et al, 1992) , consistent with the idea that an increase in expression can enhance cell growth and provide the cell tumour with a selective advantage. It is, however, possible that amplification of the gene represents general genomic instability of the tumour, or that other genes in the amplicon are exerting an effect resulting in poor prognosis. A number of more recent studies have indicated that overexpression of cyclin DI, curiously, is associated with less aggressive tumours and a better prognosis in a range of cancers. In a recent immunohistochemical study assessing cyclin Dl expression in archival invasive breast tumours (Gillett et al, 1996) , moderate/strong staining for cyclin DI was associated with improved survival. This is perhaps surprising as it is assumed that cells with increased levels of cyclin DI would be more likely to undergo deregulated proliferation, contributing to development of neoplasia. A similar effect has been observed in non-small-cell lung cancer in which cyclin Dl overexpression was associated with a lower risk of local relapse (Betticher et al, 1996) and with superficial rather than invasive stages in bladder cancer (Bringuier et al, 1996) . One possible explanation given for this is that mutations in other genes, for example Rb, might be having a dominating influence on clinical outcome in cases with low levels of cyclin Dl and associated poor prognosis. Perhaps related to these results is the finding that in neuronal cells the absolute level of cyclin Dl is critical; moderate overexpression causes growth stimulation, whereas high overexpression results in apoptotic cell death (Kranenburg et al, 1996) . If the same explanation could be extended to tumours, then the apparent paradox could be explained. For those tumours in which the cyclin Dl level exceeds the threshold for a positive regulatory effect, the cells may become apoptotic, with a resultant improved prognosis relative to tumours with lower levels of cyclin Dl. A number of other in vitro studies have provided an insight into the negative growth-regulatory effects of cyclin D1. Work by Han et al (1995) on a human mammary epithelial cell line showed that an increased expression of cyclin-Dl resulted in inhibition rather than enhancement of growth. Another possible explanation for such opposite effects could be that a moderate increase in cyclin Dl expression may have a positive effect, but a high level may be toxic to the cell. In support of this, transient overexpression of cyclin Dl in normal diploid fibroblasts efficiently blocks progression into S-phase (Atadja et al, 1995) . The fact that cyclin DI forms a ternary complex with proliferating cell nuclear antigen (PCNA), p21 and a cyclin-dependent kinase (CDK) might provide a possible mechanism for this, as high levels of cyclin DI might negatively regulate cell growth by stabilizing the CDK inhibitor p21 or by inhibiting DNA replication and repair by sequestering the PCNA protein. It can be imagined that the positive or negative regulatory function of cyclin Dl depends upon the relative levels of all of these proteins and on the cell type being studied.
In order to further elucidate the possible prognostic significance of aberrations of cell cycle components in breast carcinogenesis, it will be necessary to carry out studies similar to this one on a larger sample size and look for corfelations between protein expression and survival data.
